RecruitingPhase 2NCT07062588
Connective Tissue
Osteogenesis imperfecta type 2
2
studies recruiting now
as of 7 Sept 2026
6
studies registered in total
as of 7 Sept 2026
9
countries with a recruiting site
as of 7 Sept 2026
29 Apr 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07557446
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
Showing the 2 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Osteogenesis imperfecta type 2 studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Osteogenesis imperfecta type 2 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Osteogenesis imperfecta type 2
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (COL1A1, COL1A2, P3H1, CRTAP, PPIB, MESD).
Treatments being studied
1 approved treatment and 12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Teriparatide (Bonsity)
Phase 3Denosumab (Jubbonti)
Phase 3Risedronate Sodium (Actonel)
Phase 3Setrusumab
Phase 3Pamidronate Disodium (Aredia)
Phase 3Somatropin (Genotropin)
Phase 3Zoledronic Acid (Aclasta)
Phase 1Busulfan (Busilvex)
Phase 1Romosozumab (Evenity)
+ 4 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).